Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Completed · Phase 2

Conditions studied: Bacterial Infections, Infection

In brief

This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.

Key facts

Study ID

NCT01119105

Run by

Nabriva Therapeutics AG

People needed

210

Starts

2010-05-01

Expected to finish

2011-02-03

Last updated by the study team

2020-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients > 18
• Documented acute bacterial skin and skin structure infection

You may not qualify if…

• Uncomplicated skin and skin structure infection

Where it is running

• BC-3781 Study Center 002 — Chula Vista, California, United States
• BC-3781 Study Center 001 — La Mesa, California, United States
• BC-3781 Study Center 003 — Oceanside, California, United States
• BC-3781 Study Center 012 — Columbus, Georgia, United States
• BC-3781 Study Center 018 — Savannah, Georgia, United States
• BC-3781 Study Center 021 — Baton Rouge, Louisiana, United States
• BC-3781 Study Center 023 — Lafayette, Louisiana, United States
• BC-3781 Study Center 004 — Butte, Montana, United States
• BC-3781 Study Center 016 — Somers Point, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.